Tango Therapeutics Shares Surge Over 50% on Positive Trial Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: NASDAQ.COM
- Positive Clinical Trial Data: Tango Therapeutics' Vopimetostat shows a 90% six-month progression-free survival rate in its Phase 1/2 trial for pancreatic cancer, prompting plans to advance to Phase 3, thereby enhancing its competitive edge in cancer treatment.
- Aspire Biopharma Growth Prospects: Aspire Biopharma aims to file its NDA for high-dose sublingual aspirin by the end of 2026, and its acquisition of Dura Driver Control Systems is expected to generate over $200 million in revenue, further solidifying its market position.
- Alvotech FDA Application Progress: Alvotech's AVT16 biosimilar application has been accepted for FDA review, which is anticipated to significantly bolster its competitive stance in the biopharmaceutical market, particularly for treating Crohn's disease and ulcerative colitis.
- Zevra Patent Protection Enhancement: Zevra Therapeutics' MIPLYFFA has been listed in the Orange Book by the U.S. Patent Office, with patent protection extending to 2041, expected to significantly enhance its exclusivity and revenue potential in the rare disease market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALVO
Wall Street analysts forecast ALVO stock price to rise
4 Analyst Rating
3 Buy
0 Hold
1 Sell
Moderate Buy
Current: 4.160
Low
5.00
Averages
8.75
High
10.00
Current: 4.160
Low
5.00
Averages
8.75
High
10.00
About ALVO
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alvotech Submits BLA for AVT16 Biosimilar to Entyvio
- FDA Review Progress: Alvotech announced that the FDA has accepted its Biologics License Application (BLA) for AVT16, a biosimilar to Entyvio, marking a significant step in the company's mission to enhance access to biologic medicines, potentially boosting its market competitiveness.
- Partnership Dynamics: Under a partnership with Teva Pharmaceuticals, Alvotech is responsible for the development and manufacturing of AVT16, while Teva handles commercialization, which will help accelerate product launch and expand market reach.
- Clinical Data Support: The BLA submission is backed by a comprehensive data package, including analytical, pharmacokinetic, and immunogenicity data, which will aid in demonstrating biosimilarity between AVT16 and the reference product, enhancing confidence in regulatory approval.
- Market Potential: If approved, AVT16 will add to the biosimilar options available to patients and healthcare providers in the U.S., further advancing Alvotech's strategic positioning in the biopharmaceutical sector, particularly in treating autoimmune diseases.
See More
Tango Therapeutics Shares Surge Over 50% on Positive Trial Data
- Positive Clinical Trial Data: Tango Therapeutics' Vopimetostat shows a 90% six-month progression-free survival rate in its Phase 1/2 trial for pancreatic cancer, prompting plans to advance to Phase 3, thereby enhancing its competitive edge in cancer treatment.
- Aspire Biopharma Growth Prospects: Aspire Biopharma aims to file its NDA for high-dose sublingual aspirin by the end of 2026, and its acquisition of Dura Driver Control Systems is expected to generate over $200 million in revenue, further solidifying its market position.
- Alvotech FDA Application Progress: Alvotech's AVT16 biosimilar application has been accepted for FDA review, which is anticipated to significantly bolster its competitive stance in the biopharmaceutical market, particularly for treating Crohn's disease and ulcerative colitis.
- Zevra Patent Protection Enhancement: Zevra Therapeutics' MIPLYFFA has been listed in the Orange Book by the U.S. Patent Office, with patent protection extending to 2041, expected to significantly enhance its exclusivity and revenue potential in the rare disease market.
See More
Alvotech's AVT16 Biosimilar Application Accepted by FDA
- FDA Acceptance Milestone: Alvotech's Biologics License Application for AVT16 has been accepted by the FDA, marking a significant step in the company's mission to enhance global access to biologic medicines, which is expected to strengthen its market competitiveness.
- Strategic Partnership: Under its collaboration with Teva Pharmaceuticals, Alvotech is responsible for the development and manufacturing of AVT16, while Teva handles commercialization, a division of labor that will help expedite product launch and expand market reach.
- Biosimilar Benefits: As an interchangeable biosimilar to Entyvio, AVT16 could provide more options for patients and healthcare providers in the U.S. if approved, further driving the growth of the biosimilar market.
- Positive Market Reaction: Alvotech shares rose 12% in premarket trading to $3.97, reflecting investor optimism regarding the FDA acceptance news, which may indicate future growth potential.
See More
Veru Shares Surge 88% on Novo Nordisk Collaboration
- Veru Stock Surge: Shares of Veru Inc. (VERU) soared 88% on Thursday following a clinical supply agreement with Novo Nordisk, which involves a Phase 2b trial of its lead drug Enobosarm, potentially enhancing the company's market position in obesity treatment significantly.
- Clinical Trial Details: The PLATEAU trial will assess the effects of Enobosarm on total body weight and bone density in approximately 200 older patients with obesity, with Novo Nordisk providing Wegovy at no cost to ensure the trial's success.
- Health Catalyst Strategic Shift: Health Catalyst Inc. (HCAT) closed at $1.94, up 45.86%, as its subsidiary Vitalware was acquired by Med-Metrix, marking a new phase for the company and expected to strengthen its competitive edge in healthcare data analytics.
- Absci Clinical Progress: Absci Corp. (ABSI) shares rose 23.57% as the company advances its AI-designed antibody ABS-201 in clinical trials, with preliminary safety data expected in 2026, which could propel its growth in the biopharmaceutical sector.
See More
Alvotech Resubmits U.S. Biosimilar Applications for AVT05 and AVT06
- Stock Surge: Alvotech (ALVO) shares spiked on Thursday following the company's announcement of the resubmission of U.S. marketing applications for biosimilars targeting Johnson & Johnson's (JNJ) Simponi and Regeneron's (REGN) Eylea, reflecting market optimism about its product prospects.
- Product Positioning: AVT05 is designed as an off-patent version of JNJ's arthritis therapy for both subcutaneous and intravenous administration, while AVT06 targets Regeneron's blockbuster eye therapy Eylea (aflibercept) 2 mg, indicating Alvotech's strategic positioning in the biopharmaceutical sector.
- Application Resubmission Context: The FDA previously denied the Biologics License Applications (BLA) for AVT05 and AVT06 due to manufacturing concerns, and the resubmission includes responses to an FDA Post-Application Action Letter and results from an FDA inspection completed in May 2026, demonstrating the company's commitment to compliance.
- Review Expectations: The resubmitted BLAs are expected to undergo a six-month review by the FDA, and a successful outcome could potentially open the U.S. market for Alvotech, further enhancing its growth potential in the biosimilar sector.
See More
Alvotech Resubmits Biologics License Applications for Biosimilars
- Resubmission of Applications: Alvotech has announced the resubmission of Biologics License Applications (BLAs) for biosimilars ATV05 and ATV06, targeting chronic inflammatory diseases and retinal diseases, demonstrating the company's ongoing commitment to the biopharmaceutical sector.
- Collaborative Development: Both ATV05 and ATV06 were developed in collaboration with Teva Pharmaceutical Industries, highlighting the strategic partnership aimed at addressing the growing demand in the biosimilars market.
- FDA Review Expectations: The resubmission follows the company's response to a post-application action letter from the FDA, with expectations for a six-month review period, aligning with regulatory timelines and potentially opening new market opportunities for Alvotech.
- Market Reaction: Alvotech's stock closed at $32.83 on Thursday, down 0.76%, but showed a pre-market increase of 0.52%, indicating market interest and potential confidence in the company's biosimilar applications.
See More
Alvotech Submits BLA for AVT16 Biosimilar to Entyvio
- FDA Review Progress: Alvotech announced that the FDA has accepted its Biologics License Application (BLA) for AVT16, a biosimilar to Entyvio, marking a significant step in the company's mission to enhance access to biologic medicines, potentially boosting its market competitiveness.
- Partnership Dynamics: Under a partnership with Teva Pharmaceuticals, Alvotech is responsible for the development and manufacturing of AVT16, while Teva handles commercialization, which will help accelerate product launch and expand market reach.
- Clinical Data Support: The BLA submission is backed by a comprehensive data package, including analytical, pharmacokinetic, and immunogenicity data, which will aid in demonstrating biosimilarity between AVT16 and the reference product, enhancing confidence in regulatory approval.
- Market Potential: If approved, AVT16 will add to the biosimilar options available to patients and healthcare providers in the U.S., further advancing Alvotech's strategic positioning in the biopharmaceutical sector, particularly in treating autoimmune diseases.
See More
Tango Therapeutics Shares Surge Over 50% on Positive Trial Data
- Positive Clinical Trial Data: Tango Therapeutics' Vopimetostat shows a 90% six-month progression-free survival rate in its Phase 1/2 trial for pancreatic cancer, prompting plans to advance to Phase 3, thereby enhancing its competitive edge in cancer treatment.
- Aspire Biopharma Growth Prospects: Aspire Biopharma aims to file its NDA for high-dose sublingual aspirin by the end of 2026, and its acquisition of Dura Driver Control Systems is expected to generate over $200 million in revenue, further solidifying its market position.
- Alvotech FDA Application Progress: Alvotech's AVT16 biosimilar application has been accepted for FDA review, which is anticipated to significantly bolster its competitive stance in the biopharmaceutical market, particularly for treating Crohn's disease and ulcerative colitis.
- Zevra Patent Protection Enhancement: Zevra Therapeutics' MIPLYFFA has been listed in the Orange Book by the U.S. Patent Office, with patent protection extending to 2041, expected to significantly enhance its exclusivity and revenue potential in the rare disease market.
See More
Alvotech's AVT16 Biosimilar Application Accepted by FDA
- FDA Acceptance Milestone: Alvotech's Biologics License Application for AVT16 has been accepted by the FDA, marking a significant step in the company's mission to enhance global access to biologic medicines, which is expected to strengthen its market competitiveness.
- Strategic Partnership: Under its collaboration with Teva Pharmaceuticals, Alvotech is responsible for the development and manufacturing of AVT16, while Teva handles commercialization, a division of labor that will help expedite product launch and expand market reach.
- Biosimilar Benefits: As an interchangeable biosimilar to Entyvio, AVT16 could provide more options for patients and healthcare providers in the U.S. if approved, further driving the growth of the biosimilar market.
- Positive Market Reaction: Alvotech shares rose 12% in premarket trading to $3.97, reflecting investor optimism regarding the FDA acceptance news, which may indicate future growth potential.
See More
Veru Shares Surge 88% on Novo Nordisk Collaboration
- Veru Stock Surge: Shares of Veru Inc. (VERU) soared 88% on Thursday following a clinical supply agreement with Novo Nordisk, which involves a Phase 2b trial of its lead drug Enobosarm, potentially enhancing the company's market position in obesity treatment significantly.
- Clinical Trial Details: The PLATEAU trial will assess the effects of Enobosarm on total body weight and bone density in approximately 200 older patients with obesity, with Novo Nordisk providing Wegovy at no cost to ensure the trial's success.
- Health Catalyst Strategic Shift: Health Catalyst Inc. (HCAT) closed at $1.94, up 45.86%, as its subsidiary Vitalware was acquired by Med-Metrix, marking a new phase for the company and expected to strengthen its competitive edge in healthcare data analytics.
- Absci Clinical Progress: Absci Corp. (ABSI) shares rose 23.57% as the company advances its AI-designed antibody ABS-201 in clinical trials, with preliminary safety data expected in 2026, which could propel its growth in the biopharmaceutical sector.
See More
Alvotech Resubmits U.S. Biosimilar Applications for AVT05 and AVT06
- Stock Surge: Alvotech (ALVO) shares spiked on Thursday following the company's announcement of the resubmission of U.S. marketing applications for biosimilars targeting Johnson & Johnson's (JNJ) Simponi and Regeneron's (REGN) Eylea, reflecting market optimism about its product prospects.
- Product Positioning: AVT05 is designed as an off-patent version of JNJ's arthritis therapy for both subcutaneous and intravenous administration, while AVT06 targets Regeneron's blockbuster eye therapy Eylea (aflibercept) 2 mg, indicating Alvotech's strategic positioning in the biopharmaceutical sector.
- Application Resubmission Context: The FDA previously denied the Biologics License Applications (BLA) for AVT05 and AVT06 due to manufacturing concerns, and the resubmission includes responses to an FDA Post-Application Action Letter and results from an FDA inspection completed in May 2026, demonstrating the company's commitment to compliance.
- Review Expectations: The resubmitted BLAs are expected to undergo a six-month review by the FDA, and a successful outcome could potentially open the U.S. market for Alvotech, further enhancing its growth potential in the biosimilar sector.
See More
Alvotech Resubmits Biologics License Applications for Biosimilars
- Resubmission of Applications: Alvotech has announced the resubmission of Biologics License Applications (BLAs) for biosimilars ATV05 and ATV06, targeting chronic inflammatory diseases and retinal diseases, demonstrating the company's ongoing commitment to the biopharmaceutical sector.
- Collaborative Development: Both ATV05 and ATV06 were developed in collaboration with Teva Pharmaceutical Industries, highlighting the strategic partnership aimed at addressing the growing demand in the biosimilars market.
- FDA Review Expectations: The resubmission follows the company's response to a post-application action letter from the FDA, with expectations for a six-month review period, aligning with regulatory timelines and potentially opening new market opportunities for Alvotech.
- Market Reaction: Alvotech's stock closed at $32.83 on Thursday, down 0.76%, but showed a pre-market increase of 0.52%, indicating market interest and potential confidence in the company's biosimilar applications.
See More
